Medpace, Inc. Expands Therapeutic Capabilities With the Acquisition of Pharma Brains AG, a European CRO With Global Experience in Oncology Drug Development

CINCINNATI, OH--(Marketwire - November 02, 2009) -

Medpace, a privately held, global full-service clinical research organization, today announced it has entered into a purchase agreement to acquire Pharma Brains AG, an oncology focused CRO based in Basel, Switzerland.

Pharma Brains is an excellent fit with Medpace in terms of its complementary therapeutic expertise, strong leadership and qualified staff. Pharma Brains is led by Dr. Marc Salzberg, President and CEO, a research professional with extensive experience in oncology Phase I-IV studies as well as drug development and regulatory affairs.

“I am pleased to have Dr. Salzberg joining the group as an integral leader beginning with the integration and going forward as the VP of Oncology, Europe and General Manager, Switzerland,” said Dr. August Troendle, President and CEO, Medpace. “Marc Salzberg is a distinguished professional in European drug development and brings 17 years of industry and leadership experience to Medpace.”

The integration of Pharma Brains operations will begin immediately with the intent of completing the merger by the end of 2009.

ABOUT MEDPACE

Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry’s most experienced and therapeutically focused teams to execute at every level of the company’s operations, providing complete and seamless drug development services. In June 2009 Medpace was rated as the best CRO by U.S. Investigators in the 2009 CenterWatch Site Survey.

Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.

With more than 1000 employees and clinical trial experience in over 30 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides: Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and central image management and reading from Imagepace.

ABOUT PHARMA BRAINS AG

Founded in 1995, Pharma Brains operates as a privately held shareholder company headquartered in the biovalley of Basel, Switzerland. Pharma Brains is specialized in the areas of oncology and cardiology. Pharma Brains staff is familiar with research and development of classical pharmaceuticals, biotech products and medical devices.

Visit the Medpace website at www.medpace.com